HeartSciences Inc. HSCS 深 沪
等待开盘 03-26 09:30:00 美东时间
2.4315
+0.002
+0.06%
华盛通- 最 高2.49
- 今 开2.47
- 成交量 2119股
- 最 低 2.4212
- 昨 收 2.43
- 总市值 772.78万
- 52周最高 6.47
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 2.01
- 委 比 66.67%
- 总股本 317.82万
- 历史最高 600.00
- 量 比 0.33
- 振 幅 2.83%
- 历史最低 2.01
- 每 手 1
- 风险率 0.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
HeartSciences Inc. announced that its MyoVista Insights platform has been designated as an Epic Toolbox solution for the ECG Management System category. The cloud-native platform enhances workflow efficiency and integrates with hospital systems, including Epic, through HL7v2, SSO, and SMART on FHIR. This integration allows clinicians to access the platform seamlessly within their existing workflows. The designation, achieved after meeting Epic’s ...
03-25 12:30
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See full list & how others rate each stock.
03-24 21:40
Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $8
Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $9.2 to $8.
03-24 18:06
HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
HeartSciences Inc., a healthcare IT company advancing ECG technology with AI, will present at the Investor Summit Group Virtual Conference on March 25, 2026. The company's CEO, Andrew Simpson, will discuss its business strategy, recent achievements, and growth plans. HeartSciences also plans one-on-one investor meetings on March 26. The event aims to enhance the company's market visibility and investor engagement. For more details, visit their we...
03-24 15:18
Heart Test Laboratories Q3 EPS $(0.63) Beats $(0.86) Estimate
Heart Test Laboratories (NASDAQ:HSCS) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.86) by 26.74 percent. This is a 75.49 percent increase over losses of $(2.57) per
03-17 04:26
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
HeartSciences Inc. has reported financial results for its fiscal third quarter ended January 31, 2026, and provided updates on its MyoVista Insights healthcare IT platform and MyoVista wavECG device. The company submitted the wavECG device to the FDA for 510(k) clearance and advanced the commercialization of MyoVista Insights, which serves as a device-agnostic ECG management system. The platform has undergone upgrades, including mobile viewing an...
03-16 20:15
Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
HeartSciences Inc. announced a partnership with Cibolo Health to provide MyoVista Insights, a cloud-based ECG management platform, to 123 independent hospitals across six states. This collaboration aims to enhance workflow efficiency, data accessibility, and clinical decision-making through modernized ECG workflows and AI-integrated solutions. The partnership supports HeartSciences' mission to expand access to its platform and improve healthcare ...
01-29 13:30
HeartSciences Secures New Private Financing Through Note Issuance
Heart Test Laboratories, Inc. ( ($HSCS) ) has provided an update. On January 13...
01-17 06:53
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
